Downregulation of microRNA‐214 improves therapeutic potential of allogeneic bone marrow–derived mesenchymal stem cell by targeting PIM‐1 in rats with acute liver failure

2019 ◽  
Vol 120 (8) ◽  
pp. 12887-12903 ◽  
Author(s):  
Juan Yang ◽  
Rui Li ◽  
Dan Zhao ◽  
Sheng Zheng
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Therapeutic Potential ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone

scholarly journals Human Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Cerebellar Ataxia: A Case Report

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 334
Author(s):  
Pan-Woo Ko ◽  
Sangmin Park ◽  
Kyunghun Kang ◽  
Yong-Hyun Lim ◽  
Sang Ryong Kim ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Cerebellar Ataxia ◽  
Stem Cell Therapy ◽  
Cerebellar Atrophy ◽  
Brain Magnetic Resonance Imaging ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone

To date, there is no curable treatment option for non-hereditary degenerative cerebellar ataxia. Here we report the case of a patient with sporadic adult-onset ataxia (SAOA) who underwent allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy via the intrathecal route. A 60-year-old male patient visited our clinic complaining of progressive gait disturbance that commenced two years ago. Upon neurologic examination, the patient exhibited limb dysmetria and gait ataxia. Brain magnetic resonance imaging (MRI) revealed cerebellar atrophy whereas the autonomic function test was normal. The patient was diagnosed with SAOA. The medications that were initially prescribed had no significant effects on the course of this disease and the symptoms deteriorated progressively. At the age of 64, the patient was treated with allogeneic bone marrow-derived MSC therapy. The subsequent K-SARA (Korean version of the Scale for the Assessment and Rating of Ataxia) scores demonstrated a distinct improvement up until 10 months post-administration. No adverse events were reported. The improved post-treatment K-SARA scores may suggest that the MSC therapy can have a neuroprotective effect and that stem cell therapy may serve as a potential therapeutic option for degenerative cerebellar ataxia.

scholarly journals NG2 as an Identity and Quality Marker of Mesenchymal Stem Cell Extracellular Vesicles

Cells ◽  
2019 ◽  
Vol 8 (12) ◽  
pp. 1524 ◽  
Author(s):  
Mario Barilani ◽  
Valeria Peli ◽  
Alessandro Cherubini ◽  
Marta Dossena ◽  
Vincenza Dolo ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cord Blood ◽  
Extracellular Vesicles ◽  
Therapeutic Potential ◽  
Antigen Expression ◽  
Quality Parameter ◽  
Proliferative Effect ◽  
Quality Marker

The therapeutic potential of mesenchymal stem cell (MSC) extracellular vesicles (EV) is currently under investigation in many pathological contexts. Both adult and perinatal MSC are being considered as sources of EV. Herein, we address antigen expression of cord blood and bone marrow MSC and released EV to define an identity and quality parameter of MSC EV as a medicinal product in the context of clinical applications. The research focuses on EV-shuttled neural/glial antigen 2 (NG2), which has previously been detected as a promising surface marker to distinguish perinatal versus adult MSC. Indeed, NG2 was significantly more abundant in cord blood than bone marrow MSC and MSC EV. Ultracentrifuge-isolated EV were then challenged for their pro-angiogenic properties on an xCELLigence system as quality control. NG2+ cord blood MSC EV, but not bone marrow MSC EV, promote bFGF and PDGF-AA proliferative effect on endothelial cells. Likewise, they successfully rescue angiostatin-induced endothelial cell growth arrest. In both cases, the effects are NG2-dependent. These results point at NG2 as an identity and quality parameter for cord blood MSC EV, paving the way for their clinical translation.

scholarly journals Mesenchymal Stem Cell/Red Blood Cell-Inspired Nanoparticle Therapy in Mice with Carbon Tetrachloride-Induced Acute Liver Failure

ACS Nano ◽  
2018 ◽  
Vol 12 (7) ◽  
pp. 6536-6544 ◽  
Author(s):  
Hongxia Liang ◽  
Ke Huang ◽  
Teng Su ◽  
Zhenhua Li ◽  
Shiqi Hu ◽  
...  
Keyword(s):  
Stem Cell ◽  
Carbon Tetrachloride ◽  
Mesenchymal Stem Cell ◽  
Blood Cell ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Red Blood Cell
Sign in / Sign up

Export Citation Format

Share Document